Lupin today announced that its commercial partner, Sandoz has launched Ranluspec, Lupin's biosimilar Ranibizumab, across Europe, excluding Germany.
The launch follows the European Commission approval of Ranluspec in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.
Click here to visit SEBI Scores